Khalid Abdelshafy

Khalid Abdelshafy

Auto-generated profile, based on publicly available information

Khalid Abdelshafy

Medical Research Group of Egypt, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2019 in Current Enzyme Inhibition
Verified
Journal Article
Open access
PDF file
EBEshak I. Bahbah
Eshak I. Bahbah
AAAhmed Ramadan Abdalla
Ahmed Ramadan Abdalla
KAKhalid Abdelshafy
Khalid Abdelshafy
AAAhmed Diaa Almohandes
Ahmed Diaa Almohandes
AMAmr Menshawy
Amr Menshawy
Ahmed NegidaAhmed Negida
Ahmed Negida
Objective: The aim of this study is to synthesize the evidence about the efficacy of Olanzapine for the prevention of CINV. Methods: A computer literature search of PubMed, EBSCO, Ovid, and Cochrane CENTRAL databases has been conducted. Studies were screened for eligibility and data were extracted. The proportion of patients with complete response (CR) and those with no nausea were pooled as risk ratio (RR) in a fixed effect model meta-analysis using Review Manager Version 5.3 for windows. Results: Nine randomized controlled trials (n=1572) were pooled in the final analysis. In all studies, olanzapine was given as 10 mg PO. Olanzapine was superior to active control in terms of CR rate in acute phase (RR 1.12, 95% CI [1.02, 1.22], p=0.01]), delayed phase (RR 1.31, 95% CI [[1.10, 1.56], p=0.002), and overall phase (RR 1.30, 95% CI [1.09, 1.55], p=0.004). Rates of no nausea were significantly higher in olanzapine 10 mg group compared to active control group in acute phase (RR 1.20, 95% CI [1.04, 1.38], p=0.01), delayed phase (RR 1.72, 95% CI [1.42, 2.08], p Conclusion: Olanzapine is a well-tolerated drug for cancer patients and has shown superiority against conventional antiemetics for the prevention of CINV.